Structural Motility
![Houdusse Team Houdusse team on top of Burg building](/sites/default/files/styles/header_sciences/public/medias/images/2022-06/20190730_161718.jpg?h=1ffca8f7&itok=NyqYSnaA)
Life is driven by awe-inspiring coordinated movements observed in cells and tissues. In each cell, nm-size molecular motor proteins contribute to these movements as they power numerous mechanical processes with precision and complex orchestration. For the multiple functions that an eukaryotic cell accomplish, motility is essential both at molecular and cellular scales. Our goal is to study the principles underlying how motors convert chemical energy into mechanical movement and how biological motor proteins have evolved to enable distinct cellular function, allowing distinct generation of force precisely activated in space and time. Targeting these nanomotors can be beneficial for human health. Allosteric sites for specific small molecules can act as activators or inhibitors of the force produced by these nanomotors, and we study drugs qualified as breakthrough therapy by the FDA, currently in phase 3 clinical trials against cardiomyophathies. While frequent sites of mutations in these motors can lead to disease phenotypes, high therapeutic potential of allosteric effectors is now established and we aim to extend this knowledge to treat other pathologies, such as cancer and malaria.
-
-
-
-
Force Generation by Myosin Motors: A Structural PerspectiveChemical Reviews
-
-
Characterization of two molecules modulating cardiac contraction: one step further in precision medicineFamilial hypertrophic cardiomyopathies (FHC) are heart diseases caused by mutations in myosins, proteins responsible for heart contraction, which over the long term can lead to heart failure. The team Structural Motility led by Dr. Anne Houdusse at Institut Curie has studied the action mechanism of two molecules of therapeutic interest directly targeting the heart to treat these pathologies. These results published on June 7th, 2024, reveal crucial information about the mode of action of Mavacamten, recently approved by the FDA. This cutting-edge research paves the way for development of precision medicine for heart disease.14/06/2024
-
Structure of Resting Cardiac Myosin RevealedFor the first time ever, a team from Institut Curie has managed to observe the structure of cardiac myosin in a particular state: the sequestered state. This discovery furthers understanding of how heart muscle works and could have implications for patients with cardiomyopathy.30/06/2023
-
Cryomicroscopy: the Research Center thinks bigThe brand new Glacios Cryo-TEM™ by Thermo Fischer was received in February at Institut Curie’s Research Center, This powerful cryo-electron microscope worth over 2 million euros will enable researchers to observe proteins at unprecedented resolution. A new opportunity to understand their function and the alterations responsible for diseases, particularly cancer.17/04/2023